Search - tctmd.com

Displaying 241 - 260 of 350

Sort: Relevancy | Date

News Daily News

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Marcus A. Banks

July 12, 2019

News Daily News

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Michael O'Riordan

July 09, 2019

News Daily News

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

L.A. McKeown

June 25, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

News Daily News

Omega-3 PUFAs Offset Adverse CV Effects of Air Pollution in Small, Chinese Study

Michael O'Riordan

April 24, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

L.A. McKeown

April 17, 2019

News Daily News

Digital Tools Show Promise for Helping STEMI and NSTEMI Patients Avoid Readmission

L.A. McKeown

April 09, 2019

News Daily News

Disparities Seen in Uptake of DOACs for VTE

Todd Neale

April 05, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Daily News

‘Striking’ Improvements in Acute MI Care Over Past 20 Years, Report Shows

Michael O'Riordan

March 19, 2019

News Daily News

Rising Number of CV-Related Maternal Deaths Spurs Need for #CardioObstetrics

Caitlin E. Cox

February 27, 2019

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

Todd Neale

February 20, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

Advertisement

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

CHD Mortality Significantly Elevated in Patients With Severe FH

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Omega-3 PUFAs Offset Adverse CV Effects of Air Pollution in Small, Chinese Study

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

Digital Tools Show Promise for Helping STEMI and NSTEMI Patients Avoid Readmission

Disparities Seen in Uptake of DOACs for VTE

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

‘Striking’ Improvements in Acute MI Care Over Past 20 Years, Report Shows

Rising Number of CV-Related Maternal Deaths Spurs Need for #CardioObstetrics

Quality of CAD Care Varies by Type of Medicare Coverage

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content